5 Key Takeaways

• 1

  Michael Romansky highlighted a 3.4% increase in ASC payments for 2026, reversing an initial proposed reduction, benefiting ASCs by approximately $150 million.

• 2

  OOSS advocates for broader definitions of non-opioid drugs eligible for separate payment, aiming to include inflammation treatments in reimbursement policies.

• 3

  The Outpatient Surgery Access Act of 2026 was introduced to address longstanding reimbursement concerns, encouraging OOSS members to advocate for its support.

• 4

  OOSS emphasizes the importance of compliance with CMS regulations, warning that non-participation in prior-authorization projects may lead to non-payment.

• 5

  Romanksy urged continued member engagement in advocacy, stating that visualizing ASC facilities can effectively communicate their value to legislators.